Managing the Interplay of Familial Hypercholesterolemia and COVID-19
About 90% of those with familial hypercholesterolemia have not been diagnosed or treated for it, leaving them more vulnerable for COVID-19 infection and its complications.
Familial Hypercholesterolemia
Inclisiran Safe, Effective in Reducing LDL-C in Patients With Familial Hypercholesterolemia or ASCVD
Researchers conducted a patient-level pooled analysis from phase 3 trials of inclisiran in patients with familial hypercholesterolemia or ASCVD.
Alirocumab Approved for Homozygous Familial Hypercholesterolemia
The approval was based on data from the phase 3 ODYSSEY HoFH trial, which evaluated Praluent in 69 adults with HoFH who were on other LDL-C-lowering therapies.
Lipoprotein Apheresis Treatment for Hyperlipoproteinemia and Familial Hypercholesterolemia
Lipoprotein apheresis was associated with reduced concentrations of LDL-C and Lp(a) in patients with hyperlipoproteinemia (a) and FH on a maximally tolerated lipid-lowering regimen.
Evinacumab Lowers LDL Cholesterol in Refractory Hypercholesterolemia
In this phase 2 trial, patients with hypercholesterolemia and clinical atherosclerotic cardiovascular disease were recruited from 85 sites across 20 countries.
LDL-C Polygenic Risk Score and ASCVD in Monogenic Familial Hypercholesterolemia
Elevated LDL-C polygenic scores associated with higher LDL-C levels and increased risk for ASCVD in patients with monogenic familial hypercholesterolemia.
Dyslipidemia Medication as Thrombosis Prophylaxis in Patients With COVID-19 and FH
The treatment of patients with familial hypercholesterolemia and COVID-19 with dyslipidemia medications may prevent the occurrence of thrombotic events.
Bempedoic Acid Found to Reduce LDL-C Levels in Hypercholesterolemia, ASCVD
Bempedoic acid was found to be safe and effective at lowering LDL-C in patients with hypercholesterolemia.
What Causes Elevated Lipoprotein(a) Levels in Familial Hypercholesterolemia?
Elevated lipoprotein(a) levels was not found to be caused by FH, but may help with clinical recognition of genetic FH.
Combination Therapy of Bempedoic Acid, Ezetimibe Now Available as Adjunct to Statins
Nexlizet (bempedoic acid and ezetimibe; Esperion) is now available for use as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
- Loading...
Loading...
Next post in Cardiovascular and Metabolic Disorders
Loading... 
Loading...